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Background: Hair concentrations of antiretrovirals are an innovative and non-invasive
method for measuring cumulative antiretroviral exposure and assessing long-term antiretro
viral adherence. This study aimed to examine hair concentrations of antiretrovirals in relation
to virologic outcomes among PLHIV in Guangxi, China.
Methods: Cross-sectional data of hair concentrations of antiretrovirals and HIV viral load
were collected from 215 PLHIV in Guangxi, China. Multivariate logistic regression analyses
were used to examine the association of hair concentrations of antiretrovirals with virologic
outcomes.
Results: Of the 215 participants, 215, 67, and 163 PLHIV are receiving lamivudine,
zidovudine, and efavirenz, respectively. Multivariate analysis revealed that hair concentra
tions of lamivudine [odds ratio = 16.52, 95% CI 2.51–108.60, p = 0.004] and efavirenz [odds
ratio = 14.26, 95% CI 1.18–172.01, p = 0.036], but not zidovudine [odds ratio = 1.77, 95%
CI 0.06–56.14, p = 0.747], were the strongest independent predictor of virologic suppression
when controlling for sociodemographic and other HIV-related characteristics.
Conclusion: Hair concentrations of lamivudine and efavirenz were the strongest indepen
dent predictor of virologic suppression among Chinese PLHIV. Hair analysis of antiretrovir
als may provide a non-invasive, cost-effective tool that predicts virologic suppression among
PLHIV in China.
Keywords: hair concentrations, antiretroviral, viral load, people living with HIV
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Combination antiretroviral therapy (cART) is the primary modality for treating and
preventing HIV infection and can substantially reduce HIV-related morbidity,
mortality, and transmission.1,2 Optimal cART adherence is a critical determinant
for adequate antiretroviral exposure, which has been vital to virologic suppression
and improved clinical outcomes among people living with HIV (PLHIV).3–5 Given
the pharmacological relationship between cART adherence and antiretroviral expo
sure, analysis of antiretroviral concentrations in biological samples has been used as
an objective method for measuring antiretroviral exposure and assessing antiretro
viral adherence. Pharmacologic markers of antiretroviral exposure and antiretroviral
adherence often involve measurement of antiretroviral concentrations in biological
samples, such as plasma,6,7 urine,8 peripheral blood mononuclear cells (PMBC),9
dried blood spots (DBS),10,11 and hair.12,13 Among those metrics, plasma and urine
levels can only measure real-time or short-term antiretroviral exposure and
Patient Preference and Adherence 2021:15 853–861
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antiretroviral adherence (eg, hours to days). In addition,
plasma and urine antiretroviral levels are susceptible
to day-to-day variation.4,14 Until now, DBS levels can
measure cumulative exposure to several antiretrovirals
that are activated intracellularly4,15 and longer-term anti
retroviral adherence (eg, days to weeks). Alternatively,
hair levels can measure cumulative exposure to all
antiretrovirals4,16,17 and long-term antiretroviral adherence
(eg, weeks to months) because hair levels reflect antire
troviral uptake from the systemic circulation over weeks to
months. In addition, hair collection is non-invasive and
requires minimal training, and hair specimens can be
stored and shipped at room temperature without biohazar
dous precautions.18,19 All of these advantages make hair
concentrations of antiretrovirals appealing as an innovative
method for measuring cumulative antiretroviral exposure
and assessing long-term antiretroviral adherence.
Presently, there are more than 25 antiretrovirals in
multiple classes approved by US Food and Drug
Administration for HIV treatment, such as nucleoside
reverse transcriptase inhibitors (NRTI), non-nucleoside
reverse transcriptase inhibitors (NNRTI), protease inhibi
tors (PI), and integrase strand transfer inhibitor (INSTI, eg,
raltegravir).20 Worldwide, recommended cART is consist
ing of two or more classes of antiretrovirals. For example,
currently, WHO recommends one INSTI (eg, dolutegravir)
and two NRTIs [eg, lamivudine (3TC), zidovudine (AZT),
tenofovir (TFV)] as the first-line treatment, one NNRTI
[eg, efavirenz (EFV), nevirapine (NVP)] and two NRTIs
as alternative first-line treatment, and one PI [eg, atazana
vir (ATV) and lopinavir/ritonavir (LPV/RTV)] and two
NRTIs as the second-line treatment. As evidenced by
a comprehensive review,4 an ever-increasing body of lit
erature has shown that more than ten hair concentrations
of antiretrovirals were employed as biomarkers of cumu
lative antiretroviral exposure and/or long-term antiretro
viral adherence to predict virologic outcomes in Africa,
North America, and Europe settings. Although China
rolled out its free cART project for HIV treatment in
2004, and access to first- or second-line cART has been
scaled up across the country, limited data are available on
the association of hair concentrations of antiretrovirals
with virologic outcomes among Chinese PLHIV.
Furthermore, the simultaneous determination of hair con
centrations of antiretrovirals in multiple classes is techni
cally possible.21–24 However, major of the previous studies
only investigated the association of hair concentrations of
a single antiretroviral13,25–33 or antiretrovirals in a single
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class34 with virologic outcomes. Limited data are available
on the association of hair concentrations of antiretrovirals
in multiple classes with virologic outcomes.
Accordingly, we present this analysis of hair concen
trations of three antiretrovirals (3TC, AZT, and EFV) in
two classes (NRTI and NNRTI) in relation to virologic
outcomes among Chinese PLHIV.

Materials and Methods
Participants
The participants of this study were recruited from Wave 3
of the HIV disclosure project, which is a longitudinal
study that aims to explore the mechanism underlying the
linkage between HIV disclosure and clinical outcomes in
Guangxi, China.35–37 With the Guangxi Center for Disease
Prevention and Control (Guangxi CDC) ‘s assistance and
collaboration, we randomly selected 10 clinic sites with
the largest number of HIV/AIDS cases from 17 cities and
75 counties in Guangxi. The recruitment procedure,
including inclusion and exclusion criteria, was described
in the previous studies.35 Briefly, medical staff or HIV
case managers at the study sites referred potential partici
pants to the research team members. Research team mem
bers screened PLHIV for eligibility, discussed the benefits
and risks of the study, and invited them to participate.
Research team members were local CDC staff or health
care workers in the HIV clinics who had received inten
sive training on research ethics and interview skills with
PLHIV before the field data and hair specimen collection.
Finally, a total of 446 PLHIV participated in Wave 1 of the
HIV disclosure project, and 428 PLHIV participated in
Wave 3 of the HIV disclosure project.
This study followed the Declaration of Helsinki and
was approved by ethical review boards of the University
of South Carolina (Columbia, USA) and the Guangxi
Zhuang Autonomous Region Center for Disease
Prevention and Control (Nanning, China). The written
informed consent also has been obtained from the
participants.

Hair Sample Collection and Assay
Hair samples were cut from the posterior vertex region as
close as possible to the scalp following a standard
protocol38,39 after participants finished the survey. The
hair sample (about 1 cm of the proximal section) was
rinsed with methanol and dried under a blow of pure
nitrogen gas. Then, hair sample was chopped to 1–2 mm
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length segments with scissors, and 10 mg weighed, pro
cessed, and analyzed using high-performance liquid chro
matography (Agilent 1200 HPLC system, Agilent,
Waldbronn, Germany) and tandem mass spectrometry
(ABI 3200Qtrap, ABI, Foster City, CA, USA) (LC-MS
/MS) as described in previous studies.21,24,40 Briefly, fol
lowing the 2013 FDA guidelines, antiretrovirals in the cut
hair samples were extracted with methanol and internal
standard in a 37°C shaking water bath overnight (>16
hours) and then analyzed by an LC-MS/MS. Standard
curves were linear in the range of 6–40,000 pg for 3TC,
10–40,000 pg for AZT, and 12–40,000 pg for EFV with
good linearity and reproducibility. The relative error (%)
and precision [coefficients of variation] for spiked quality
control hair samples at low, medium, and high concentra
tions were all <13%. The recoveries at low, medium, and
high concentrations were all ≥91.1%. The lower limit of
quantitation was 6 pg/mg, 10 pg/mg, and 12 pg/mg for
3TC, AZT, and EFV.

Sociodemographic and HIV-Related
Characteristics
Participants provided information on their sociodemo
graphic characteristics, including age (years), gender
(male vs female), ethnicity (Han vs non-Han), marital
status (married vs other), education level (>9 years vs ≤9
years), employment status (employed vs unemployed),
monthly household income level (≥2000 Chinese Yuan
vs <2000 Chinese Yuan).
The participants’ HIV viral load and other HIV-related
characteristics at the time of hair collection, including date
of HIV diagnosis, current cART status, date of starting
current cART, and CD4 count, were extracted from their
clinical records. Given that the “Undetectable =
Untransmittable” initiative defined undetectable viral load
as viral load less than 200 copies/mL that cannot sexually
transmit HIV to others,41 we defined virologic suppression
as viral load less than 200 copies/mL, and virologic failure
as viral load equal or more than 200 copies/mL. Years of
HIV diagnosis and current cART referred to the time
period from the initial date of confirmed HIV diagnosis
and the start date of current cART to the date of hair
collection, respectively. The cART status was category
into first-line and second-line cART. CD4count was
dichotomized as ≥350 cells/mm3 vs <350 cells/mm3
because free cART was offered to PLHIV, whose CD4
count was less than 350 cells/mm3.
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Self-reported adherence was determined by asking par
ticipants to indicate how often they took their antiretrovir
als as prescribed in the past month. Response options
ranged from 1 (100% of the time) to 5 (I have not taken
any of my prescribed medications). This measure has been
found to predict CD4+ T cell counts and viral load as well
as, or better than, other measures of self-reported
adherence.42 Given that self-reported data are generally
skewed and overestimated, we dichotomized self-reported
adherence to 100% and less than 100%.36

Statistical Analysis
Of 428 PLHIV, 213 were excluded from the final analysis
because they had not yet started cART (n=13) or stopped
cART (n=2) or unavailable HIV viral load (n=198), leav
ing an effective sample of 215 participants for analysis.
Descriptive statistics were used to summarize hair con
centrations of antiretrovirals, sociodemographic, and HIVrelated characteristics. Categorized data were expressed as
number (n) and percentage (%). A one-sample Shapiro–
Wilks test was used to examine normally distributed data.
Non-normally distributed data were expressed as the med
ian and interquartile range (IQR), and normally distributed
data were expressed as mean (M) and standard deviation
(SD). Chi-square test (for categorical variables), t-test (for
normally distributed continuous variables), and Mann–
Whitney U-test (for non-normally distributed continuous
variables) were used to compare differences between the
virologic suppression and virologic failure groups in terms
of the sociodemographic, hair concentrations of antiretro
virals, and other HIV-related characteristics. Spearman
correlation analysis was performed to examine the asso
ciation among hair concentrations of antiretrovirals and
the association of hair concentrations of antiretrovirals
with sociodemographic and other HIV-related variables.
Multivariate linear regression analysis was used to check
for collinearity, and all variables showed good tolerance
(>0.1) and variance inflation factors (<10). Logistic regres
sion analysis was used to estimate the association of hair
concentrations of antiretrovirals (3TC, AZT, and EFV sepa
rately) with the dichotomous outcome of virologic response.
Hair concentrations of 3TC, AZT, and EFV tertiles were
calculated, and the second and third tertiles were contrasted
with the first tertile as the reference category. The univariate
logistic regression model was used to examine those asso
ciations. To fully control the potential impact of sociodemo
graphics and other HIV-related variables on virologic
response, the multivariate logistic regression model with
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the enter method was used to examine those associations
adjusting sociodemographics and other HIV-related vari
ables. Crude odds ratios (cORs) and their 95% confidence
interval (95% CI) were reported for univariate analysis, and
adjusted odds ratios (aORs) and their 95% CI were reported
for multivariate analysis. All data analyses were performed
using SPSS 26.0 (SPSS Inc., Chicago, IL).

Results
Of the 215 PLHIV with a mean (SD) age of 41 (8) years
(Table 1), 68.4% were male, 55.7% were Han ethnicity,

78.6% were married, 86.5% were employed, 86% were
receiving the first-line cART, 84.2% were reporting 100%
cART adherence, 52.6% were achieving CD4 count- ≥ 350
cells/mm3, and 91.6% were achieving virologic suppres
sion. Most of the sample had low levels of education and
income, with 96.1% reporting not complete junior high
school and 54% reporting a monthly household income of
less than 2000 Chinese Yuan (or approximately US$300
during the time of the study). The median years of HIV
diagnosis and current cART were 2.8 years and 2.7 years.
Significant differences between virologic suppression and

Table 1 Sociodemographic and HIV-Related Characteristics of Participants
Characteristics

Total

Virologic Suppression

Virologic Failure

n=215 (100%)

n=197 (91.6%)

n=18 (8.4%)

43.13 ± 8.31

43.44 ± 11.71

43.10 ±7.97

0.865

Male

147 (68.4%)

137 (69.5%)

10 (55.6%)

0.222

Female

68 (31.6%)

60 (30.5%)

8 (44.4%)

Han
No-Han

122 (56.7%)
93 (44.3%)

113 (57.4%)
84 (42.6%)

9 (50.0%)
9 (50.0%)

0.546

Marital status
Married

169 (78.6%)

157(79.7%)

12 (66.7%)

0.197

Others

46 (21.4%)

40 (20.3%)

6 (33.3%)

> 9 years

18 (8.4%)

18 (9.1%)

0 (0%)

≤ 9 years

197 (91.6%)

179 (90.9%)

18 (100%)

186 (86.5%)
29 (13.5%)

172 (87.3%)
25 (12.7%)

14 (77.8%)
4 (22.2)

0.257

99 (46.0%)

92 (46.7%)

7 (38.9%)

0.524

116 (54.0%)

105 (53.3%)

11 (61.6%)

Years of HIV diagnosis, years

2.8 (2.3–3.4)

2.8 (2.3–3.4)

2.5 (1.9–3.3)

0.228

Current cART status
First-line cART

185 (86.0%)

173 (87.8%)

12 (66.7%)

0.013

30 (14.0%)

24 (12.2%)

6 (33.3%)

2.7 (2.3–3.4)

2.8 (2.3–3.4)

2.5 (1.9–3.2)

0.249

102(47.4%)
113(52.6%)

88 (44.7%)
109 (55.3%)

14 (77.8%)
4 (22.4%)

0.007

181 (84.2%)

167 (93.2%)

14 (77.8%)

0.436

34 (15.8%)

30 (15.2%)

4 (22.2%)

Age, years

p-value

Gender

Ethnicity

Education levels
0.180

Employment status
Employed
Unemployed
Monthly income levels
≥2000 Chinese Yuan
<2000 Chinese Yuan

Second-line cART
Years of current cART, years
CD4 count-, cells/mm3
< 350
≥ 350
Self-reported adherence
100%
Less than 100%

Abbreviation: cART, combination antiretroviral therapy.
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Table 2 Correlation Between Hair Concentrations of Antiretrovirals and Sociodemographic and Other Clinical Characteristics
Characteristics

3TC Concentrations

AZT Concentrations

EFV Concentrations

N=215

N=67

N=163

r

p-value

r

p-value

r

p-value

Age

0.100

0.142

0.026

0.836

0.005

0.947

Gender

0.114

0.097

0.188

0.127

0.127

0.107

Ethnicity

−0.034

0.662

0.123

0.321

0.083

0.293

Marital status

−0.050

0.468

0.022

0.863

−0.089

0.259

Education levels

0.120

0.080

0.043

0.730

−0.023

0.770

Employment status

−0.170

0.013

−0.130

0.294

−0.028

0.724

Monthly income levels

0.112

0.102

0.193

0.024

0.031

0.693

Years of HIV diagnosis

0.105

0.125

−0.097

0.435

−0.126

0.108

Current cART satus

0.127

0.063

−0.245

0.045

-

-

Years of current cART

0.114

0.096

−0.097

0.435

−0.090

0.252

Self-reported adherence

0.181

0.008

0.340

0.005

0.149

0.057

CD4 count

−0.016

0.811

0.240

0.097

−0.104

0.186

Abbreviations: cART, combination antiretroviral therapy; 3TC, lamivudine; AZT, zidovudine; EFV, efavirenz.

virologic failure groups were only found in current cART
status (p = 0.013) and CD4 count (p = 0.007).
As shown in Table 2, marginal or significant correla
tion was found between hair 3TC concentrations and gen
der (p = 0.097), education levels (p = 0.080), employment
status (p = 0.013), current cART status (p = 0.063), years
of current cART (p = 0.096) and self-reported adherence
(p = 0.008), between hair AZT concentrations and monthly
income levels (p = 0.024), current cART status (p = 0.045),
self-reported adherence (p = 0.005) and CD4 count (p =
0.097), and between hair EFV concentrations and selfreported adherence (p = 0.057). In addition, positive cor
relations were found between hair 3TC concentrations and
hair AZT concentrations (n = 68, r = 0.465, p < 0.001),
between hair 3TC concentrations and hair EFV

concentrations (n = 163, r = 0.414, p < 0.001), and
between hair AZT concentrations and hair EFV concentra
tions (n=38, r = 0.597, p < 0.001).
As shown in Table 3, of the 215 participants, 215, 67,
and 163 PLHIV are receiving 3TC, AZT, and EFV, and
197, 60, and 153 PLHIV are achieving virologic suppres
sion, respectively. PLHIV with virologic suppression had
significant higher hair concentrations of 3TC, AZT, and
EFV than those with virologic failure (p = 0.008, p =
0.016, and p = 0.030, respectively). The median and inter
quartile range (IQR) of hair concentrations of 3TC, AZT,
and EFV among those with virological suppression was
476.55 (315.33–695.38) pg/mg, 289.48 (166.35–471.21)
pg/mg, and 4814.74 (3472.07–7111.86) pg/mg, respec
tively. The value of 315.33 pg/mg, 166.35 pg/mg, and

Table 3 Hair Concentrations of Antiretrovirals by the Virologic Outcome
Antiretrovirals

Virologic Suppression

Virologic Failure

p-value

n

Median (IQR), pg/mg

n

Median (IQR), pg/mg

3TC

197

476.55 (315.33–695.38)

18

247.42 (36.66–454.67)

0.008

AZT

60

289.48 (166.35–471.21)

7

10.00 (10.00–185.98)

0.016

EFV

153

4814.74 (3472.07–7111.86)

10

3262.33 (53.18–5252.53)

0.030

Abbreviations: IQR, interquartile range; 3TC, lamivudine; AZT, zidovudine; EFV, efavirenz.
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Table 4 Logistic Regression Results Predicting Virologic Suppression Based on Hair Concentrations of Antiretrovirals
Univariate

Multivariate

n (%)

cORs (95% CI)

p

aORs (95% CI)

p

Lowest tertile
Middle tertile

60 (84.5%)
67 (94.4%)

1.00 (ref)
3.07 (0.93–10.16)

–
0.066

1.00(ref)
5.65 (1.21–26.34)

–
0.028

Highest tertile

70 (95.9%)

4.28 (1.14–16.05)

0.031

16.52 (2.51–108.60)

0.004

Lowest tertile

17 (77.3%)

1.00 (ref)

–

Middle tertile
Highest tertile

21 (95.5%)
22 (95.7%)

6.18 (0.66–58.03)
6.47 (0.69–60.68)

0.111
0.102

1.06 (0.02–47.85)
1.77 (0.06–56.14)

0.976
0.747

EFV (n=163)
Lowest tertile

49 (90.7%)

1.00 (ref)

–

Middle tertile

50 (92.6%)

1.28 (0.32–5.02)

0.728

1.72 (0.34–8.78)

0.511

Highest tertile

54 (98.2%)

5.51 (0.62–48.82)

0.125

14.26 (1.18–172.01)

0.036

3TC (n=215)

AZT (n=67)

Abbreviations: CI, confidence interval; cOR, crude odds ratio; aOR, adjusted odds ratio; 3TC, lamivudine; AZT, zidovudine; EFV, efavirenz.

3472.07 pg/mg (lower IQR for those with virological
suppression) defined a cut-off below which most partici
pants experienced virological failure.
The results of logistic regression models of virologic
suppression are presented in Table 4. The cORs were 4.28
[95% CI 1.14–16.05, p=0.031], 6.47 [95% CI 0.69–60.68,
p=0.102], and 5.51 [95% CI 0.62–48.82, p=0.125] for those
with hair concentrations of 3TC, AZT, and EFV in the
highest tertile compared to the lowest tertile in univariate
analysis. The aORs were 16.52 [95% CI 2.51–108.60,
p=0.004], 1.77 [95% CI 0.06–56.14, p=0.747], and 14.26
[95% CI 1.18–172.01, p=0.036] for those with hair concen
trations of 3TC, AZT, and EFV in the highest quartile
compared to the lowest quartile when controlling for socio
demographic and other HIV-related characteristics.

Discussion
Our study is the first to examine the association of hair
concentrations of various antiretrovirals with virologic
outcomes in a cohort of Chinese PLHIV on cART. We
show that, while hair concentrations of 3TC, AZT, and
EFV were significantly higher in PLHIV with virologic
suppression than those with virologic failure, hair concen
trations of 3TC and EFV, but not AZT, are the strongest
independent predictor of virologic suppression when con
trolling for sociodemographic, and other HIV-related char
acteristics. In addition, we found positive correlations
among hair concentrations of antiretrovirals and between
self-reported adherence and hair concentrations of
antiretrovirals.
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Our results regarding PLHIV with virologic suppres
sion had higher hair concentrations of 3TC, AZT, and EFV
than those with virologic failure were in line with previous
studies employing hair concentrations of 3TC,13 EFV,12,43
TFV,33 NVP,12 LPV,12,29,31,34,43 RTV,12,29,34 ATV34,44 and
indinavir.25–27 Interestingly, our study revealed that hair
concentrations of 3TC and EFV, but not AZT, are the
strongest independent predictor of virologic suppression.
Our findings of hair concentrations of 3TC and EFV added
evidence to existing studies that reported that hair concen
trations of antiretrovirals (eg, TFV,33 EFV,43,45 NVP,30
LPV,31,32,34 ATV28,34) were the strongest independent pre
dictor of virologic suppression. Regarding the nonsignifi
cant finding of hair AZT concentrations, the small sample
size and lower hair AZT concentrations could contribute to
this finding. As seen in Table 3, among 215 PLHIV on
cART, only 67 PLHIV were receiving AZT-based cART,
and hair AZT concentrations were much lower than hair
concentrations of 3TC and EFV.
We found a positive correlation between self-reported
adherence and hair concentrations of 3TC, AZT, and EFV,
which was partly in line with previous studies by using
hair concentrations of antiretrovirals (eg, ATV28 and
TFV36). This finding might also indicate that our study’s
adherence measure could be better detection of cART
adherence.42 In addition, we found positive correlations
among hair concentrations of 3TC, AZT, and EFV, which
might indicate a significant drug–drug interaction among
those antiretrovirals. Moreover, we found that hair 3TC
concentrations were easily affected by sociodemographic
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and HIV-related characteristics than hair concentrations of
AZT and EFV did (Table 2), which added not only the
understanding of the factors related to hair concentrations
of antiretrovirals,19,37 but also the potential reason that hair
EFV concentrations had higher effect than hair 3TC con
centrations, in addition to hair EFV concentrations are
much higher than hair 3TC concentrations.
Our study has several limitations. First, the current
study was based on cross-sectional data, which prevents
making causal inferences. Second, the current study only
employed hair concentrations of three antiretrovirals.
Future studies should examine some other commonly
used free antiretrovirals (eg, TFV, NVP, and LPV/RTV)
in a large sample size with a more innovative methodology
(eg, machine learning). Third, we employed the lower IQR
of hair concentrations of antiretrovirals for those with
virologic- suppression as the recommended cut-offs for
viral failures based on the Chawana et al.44 Future studies
should determine such cut-offs using pharmacokinetic
modeling.46 Fourth, because all participants were from
Guangxi, China, these findings may not be generalizable
to PLHIV in other settings. Future research should employ
both Chinese PLHIV and PLHIV in other countries to
examine the association between hair concentrations of
antiretrovirals with virologic outcomes. Finally, data
were not available in the current study on some factors
(eg, illegal drugs use) that might influence virologic out
comes or hair concentrations of antiretrovirals.19 Those
factors should be considered in future research.

Conclusion
In summary, our findings indicated that hair concentrations
of antiretrovirals were significantly associated with virologic
outcomes among Chinese PLHIV. Hair analysis of antiretro
virals may provide a non-invasive, cost-effective tool that
predicts virologic suppression among Chinese PLHIV.

Acknowledgments
The authors thank the study participants and data collec
tors for their collaboration during the data collection. Quan
Zhang and Yuejiao Zhou share co-first authorship.

Funding
This study was supported by the National Institutes of
Health (NIH) Research Grant [Grant numbers
R01HD074221, R21AI122919].

Patient Preference and Adherence 2021:15

Zhang et al

Disclosure
The authors report no conflicts of interest in this work.

References
1. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for
treatment and prevention of HIV infection in adults: 2018 recommen
dations of the international antiviral society-USA panel. JAMA.
2018;320(4):379–396. doi:10.1001/jama.2018.8431
2. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence
to HIV treatment regimens: systematic literature review and
meta-analysis. Patient Prefer Adherence. 2019;13:475–490.
doi:10.2147/PPA.S192735
3. Robbins RN, Spector AY, Mellins CA, Remien RH. Optimizing ART
adherence: update for HIV treatment and prevention. Curr HIV/AIDS
Rep. 2014;11(4):423–433. doi:10.1007/s11904-014-0229-5
4. Zhang Q, Qiao S, Yang X, Li X. Antiretroviral concentration in hair
as a measure for antiretroviral medication adherence: a systematic
review of global literature. AIDS Behav. 2020;24(1):311–330.
doi:10.1007/s10461-019-02460-5
5. Saberi P, Ming K, Legnitto D, Neilands TB, Gandhi M, Johnson MO.
Novel methods to estimate antiretroviral adherence: protocol for
a longitudinal study. Patient Prefer Adherence. 2018;12:1033–1042.
doi:10.2147/PPA.S166380
6. Marzolini CTA, Decosterd LA, Greub G, Biollaz J, Buclin T.
Efavirenz plasma levels can predict treatment failure and central
nervous system side effects in HIV-1-infected patients. AIDS.
2001;15(1):71–75. doi:10.1097/00002030-200101050-00011
7. Mwasakifwa GE, Moore C, Carey D, et al. Relationship between
untimed plasma lopinavir concentrations and virological outcome on
second-line antiretroviral therapy. AIDS. 2018;32(3):357–361.
doi:10.1097/QAD.0000000000001688
8. Gandhi M, Bacchetti P, Spinelli MA, et al. Brief report: validation of
a urine tenofovir immunoassay for adherence monitoring to PrEP and
ART and establishing the cutoff for a point-of-care test. J Acquir Immune
Defic Syndr. 2019;81(1):72–77. doi:10.1097/QAI.0000000000001971
9. Baxi SM, Liu A, Bacchetti P, et al. Comparing the novel method of
assessing PrEP adherence/exposure using hair samples to other phar
macologic and traditional measures. J Acquir Immune Defic Syndr.
2015;68(1):13–20. doi:10.1097/QAI.0000000000000386
10. Frasca K, Morrow M, Coyle RP, et al. Emtricitabine triphosphate in
dried blood spots is a predictor of viral suppression in HIV infection
and reflects short-term adherence to antiretroviral therapy.
J Antimicrob Chemother. 2019;74(5):1395–1401. doi:10.1093/jac/
dky559
11. Morrow M, MaWhinney S, Coyle RP, et al. Predictive value of
tenofovir diphosphate in dried blood spots for future viremia in
persons living with HIV. J Infect Dis. 2019;220(4):635–642.
doi:10.1093/infdis/jiz144
12. Tabb ZJ, Mmbaga BT, Gandhi M, et al. Antiretroviral drug concen
trations in hair are associated with virologic outcomes among young
people living with HIV in Tanzania. AIDS. 2018;32(9):1115–1123.
doi:10.1097/QAD.0000000000001788
13. Yan J, Liu J, Su B, et al. Lamivudine concentration in hair and
prediction of virologic failure and drug resistance among HIV
patients receiving free ART in China. PLoS One. 2016;11(4):
e0154421. doi:10.1371/journal.pone.0154421
14. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual
variability in antiretroviral concentrations may limit the utility of
therapeutic drug monitoring. Clin Infect Dis. 2006;42(8):1189–1196.
doi:10.1086/501458
15. Gandhi M, Gandhi RT, Stefanescu A, et al. Cumulative antiretroviral
exposure measured in hair is not associated with measures of HIV
persistence or inflammation among individuals on suppressive ART.
J Infect Dis. 2018;218(2):234–238. doi:10.1093/infdis/jiy011

http://doi.org/10.2147/PPA.S277965

DovePress

Powered by TCPDF (www.tcpdf.org)

859

Zhang et al
16. Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV:
new advancements in pharmacologic methods and real-time
monitoring. Curr HIV/AIDS Rep. 2018;15(1):49–59. doi:10.1007/
s11904-018-0377-0
17. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitor
ing antiretroviral treatment. Ann Intern Med. 2002;137(8):696–697.
doi:10.7326/0003-4819-137-8-200210150-00016
18. Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentra
tions in small hair samples as a feasible marker of adherence in rural
Kenya. J Acquir Immune Defic Syndr. 2014;66(3):311–315.
doi:10.1097/QAI.0000000000000154
19. Zhang Q, Li X, Qiao S, Yang X. Factors related to hair antiretroviral
concentration: a systematic review of global literature. AIDS Rev.
2020;22(1):25–33. doi:10.24875/AIDSRev.19000122
20. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25
years after the discovery of HIV. Int J Antimicrob Agents. 2009;33
(4):307–320. doi:10.1016/j.ijantimicag.2008.10.010
21. Chu L, Wu Y, Duan C, et al. Simultaneous quantitation of zidovu
dine, efavirenz, lopinavir and ritonavir in human hair by liquid
chromatography-atmospheric pressure chemical ionization-tandem
mass spectrometry. J Chromatogr B Analyt Technol Biomed Life
Sci. 2018;1097-1098:54–63. doi:10.1016/j.jchromb.2018.08.031
22. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N.
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritona
vir, in human hair by liquid chromatography coupled with tandem
mass spectrometry. Rapid Commun Mass Spectrom. 2008;22
(21):3401–3409. doi:10.1002/rcm.3750
23. Shah SA, Mullin R, Jones G, et al. Simultaneous analysis of anti
retroviral drugs abacavir and tenofovir in human hair by liquid
chromatography-tandem mass spectrometry. J Pharm Biomed Anal.
2013;74:308–313. doi:10.1016/j.jpba.2012.10.023
24. Wu Y, Yang J, Duan C, et al. Simultaneous determination of anti
retroviral
drugs
in
human
hair
with
liquid
chromatography-electrospray ionization-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci.
2018;1083:209–221. doi:10.1016/j.jchromb.2018.03.021
25. Bernard L, Peytavin G, Vuagnat A, de Truchis P, Perronne C.
Indinavir concentrations in hair from patients receiving highly active
antiretroviral therapy. The Lancet. 1998;352(9142):1757–1758.
doi:10.1016/S0140-6736(05)79831-7
26. Bernard L, Vuagnat A, Peytavin G, et al. Relationship between levels
of indinavir in hair and virologic response to highly active antiretro
viral therapy. Ann Intern Med. 2002;137(8):656–659. doi:10.7326/
0003-4819-137-8-200210150-00009
27. Duval X, Peytavin G, Breton G, et al. Hair versus plasma concentra
tions as indicator of indinavir exposure in HIV-1-infected patients
treated with indinavir/ritonavir combination. AIDS. 2007;21
(1):106–108. doi:10.1097/QAD.0b013e3280118486
28. Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in
hair is the strongest predictor of outcomes on antiretroviral therapy.
Clin Infect Dis. 2011;52(10):1267–1275. doi:10.1093/cid/cir131
29. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma
or hair concentrations explain second-line protease inhibitor failures
in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56
(4):333–339. doi:10.1097/QAI.0b013e31820dc0cc
30. Baxi SM, Greenblatt RM, Bacchetti P, et al. Nevirapine concentration
in hair samples is a strong predictor of virologic suppression in
a prospective cohort of HIV-infected patients. PLoS One. 2015;10
(6):e0129100. doi:10.1371/journal.pone.0129100

860

Powered by TCPDF (www.tcpdf.org)

http://doi.org/10.2147/PPA.S277965

DovePress

Dovepress
31. Prasitsuebsai W, Kerr SJ, Truong KH, et al. Using lopinavir concen
trations in hair samples to assess treatment outcomes on second-line
regimens among Asian children. AIDS Res Hum Retroviruses.
2015;31(10):1009–1014. doi:10.1089/aid.2015.0111
32. Pintye J, Bacchetti P, Teeraananchai S, et al. Brief report: lopinavir
hair concentrations are the strongest predictor of viremia in
HIV-infected Asian children and adolescents on second-line antire
troviral therapy. J Acquir Immune Defic Syndr. 2017;76(4):367–371.
doi:10.1097/QAI.0000000000001527
33. Murnane PM, Bacchetti P, Currier JS, et al. Tenofovir concentrations
in hair strongly predict virologic suppression in breastfeeding
women.
AIDS.
2019;33(10):1657–1662.
doi:10.1097/
QAD.0000000000002237
34. Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in
hair strongly predict virologic response to treatment. AIDS. 2009;23
(4):471–478. doi:10.1097/QAD.0b013e328325a4a9
35. Yang X, Li X, Qiao S, Zhang Q, Shen Z, Zhou Y. Immunological and
virologic outcomes of people living with HIV in Guangxi, China:
2012-2017. PLoS One. 2019;14(3):e0213205. doi:10.1371/journal.
pone.0213205
36. Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Comparing self-reported
medication adherence measures with hair antiretroviral concentration
among people living with HIV in Guangxi, China. AIDS Res Ther.
2020;17(1):8. doi:10.1186/s12981-020-00265-4
37. Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Factors influencing hair
lamivudine concentration among people living with HIV in Guangxi,
China. Antivir Ther. 2020;25(3):143–149. doi:10.3851/IMP3360
38. Cooper GA, Kronstrand R, Kintz P, Society of Hair T. Society of hair
testing guidelines for drug testing in hair. Forensic Sci Int. 2012;218
(1–3):20–24. doi:10.1016/j.forsciint.2011.10.024
39. Sachs H. Quality control by the society of hair testing. Forensic Sci
Int. 1997;84(1–3):145–150. doi:10.1016/S0379-0738(96)02057-9
40. Yang H, Chu L, Wu Y, et al. LC-MS/MS quantification of nevirapine
and its metabolites in hair for assessing long-term adherence.
Molecules. 2020;25:23. doi:10.3390/molecules25235692
41. Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and trans
missibility of HIV infection: undetectable equals untransmittable.
JAMA. 2019;321(5):451–452. doi:10.1001/jama.2018.21167
42. Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the
single-item self-rating adherence scale for use in routine clinical care
of people living with HIV. AIDS Behav. 2013;17(1):307–318.
doi:10.1007/s10461-012-0326-7
43. Koss CA, Natureeba P, Mwesigwa J, et al. Hair concentrations of
antiretrovirals predict viral suppression in HIV-infected pregnant and
breastfeeding Ugandan women. AIDS. 2015;29(7):825–830.
doi:10.1097/QAD.0000000000000619
44. Chawana TD, Gandhi M, Nathoo K, et al. Defining a cutoff for
atazanavir in hair samples associated with virological failure among
adolescents failing second-line antiretroviral treatment. J Acquir
Immune
Defic
Syndr.
2017;76(1):55–59.
doi:10.1097/
QAI.0000000000001452
45. Cohan D, Natureeba P, Koss CA, et al. Efficacy and safety of
lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in
HIV-infected pregnant Ugandan women. AIDS. 2015;29
(2):183–191. doi:10.1097/QAD.0000000000000531
46. Ngara B, Zvada S, Chawana TD, Stray-Pedersen B, Nhachi CFB,
Rusakaniko S. A population pharmacokinetic model is beneficial in
quantifying hair concentrations of ritonavir-boosted atazanavir:
a study of HIV-infected Zimbabwean adolescents. BMC Pharmacol
Toxicol. 2020;21(1):58. doi:10.1186/s40360-020-00437-y

Patient Preference and Adherence 2021:15

Dovepress

Zhang et al

Dovepress

Patient Preference and Adherence

Publish your work in this journal
Patient Preference and Adherence is an international, peer-reviewed,
open access journal that focusing on the growing importance of
patient preference and adherence throughout the therapeutic conti
nuum. Patient satisfaction, acceptability, quality of life, compliance,
persistence and their role in developing new therapeutic modalities
and compounds to optimize clinical outcomes for existing disease

states are major areas of interest for the journal. This journal has
been accepted for indexing on PubMed Central. The manuscript
management system is completely online and includes a very quick
and fair peer-review system, which is all easy to use. Visit http://
www.dovepress.com/testimonials.php to read real quotes from pub
lished authors.

Submit your manuscript here: https://www.dovepress.com/patient-preference-and-adherence-journal

Patient Preference and Adherence 2021:15

Powered by TCPDF (www.tcpdf.org)

DovePress

861

